Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TET2 | Q6N021 | 6/20 | 0.46 |
| ▸ | TET3 | O43151 | 2/20 | 0.46 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 2/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.43 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.43 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.37 |
| ▸ | PGK1 | P00558 | 1/20 | 0.37 |
| ▸ | PGK2 | P07205 | 1/20 | 0.37 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL721067 | 0.79 | — | — | |
| SCHEMBL13677846 | 0.79 | — | — | |
| SCHEMBL1405991 | 0.79 | — | — | |
| SCHEMBL16289579 | 0.78 | OR51E2 (0.37) | OR51E2SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL19956884 | 0.77 | — | — | |
| SCHEMBL724401 | 0.75 | — | — | |
| SCHEMBL7442197 | 0.75 | — | — | |
| SCHEMBL8712420 | 0.73 | CYP2D6 (0.37) | OR51E2TET2TET3TET1TSHR | |
| SCHEMBL9242381 | 0.73 | OR51E2 (0.42) | OR51E2SMN1; SMN2TET2TET3TET1 | |
| SCHEMBL9242389 | 0.73 | OR51E2 (0.42) | OR51E2SMN1; SMN2TET2TET3TET1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4127596-A1 | AMMUNITION CARTRIDGE CONTAINING A POLYMER COMPOSITION | Ticona LLC (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021126742-A1 | POWDER BED FUSION PRINTING SYSTEM EMPLOYING A POLYARYLENE SULFIDE POWDER | TICONA LLC (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2019173428-A1 | POLYARYLETHERKETONE COMPOSITION | TICONA LLC (US) | 2019-09-12 | — | — | WO | disclosed |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2019-01-31 | — | — | US | disclosed |
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | PCR TECHNOLOGY HOLDINGS, LC (US) | 2018-11-13 | — | — | US | disclosed |
| WO-2017147146-A1 | PRODRUGS OF PHENOLIC TRPV1 AGONISTS | Concentric Analgesics, Inc. (US) | 2017-08-31 | — | — | WO | disclosed |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | Dermaforce Holdings, LLC | 2016-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10123960-B2 | Methods for treating of skin conditions with retinoid double conjugate compounds | RARA, LRAT, RARG | OR51E2 814/4885SMN1; SMN2 2688/4885TET2 3046/4885 |
| US-20190029941-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | OR51E2 2371/4885SMN1; SMN2 2368/4885TET2 3782/4885 |
| US-20160287507-A1 | RETINOID DOUBLE CONJUGATE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS FOR TREATING OF SKIN CONDITIONS | RARA, RARG, RXRA | OR51E2 926/4885SMN1; SMN2 2780/4885TET2 2816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.